Clinical Trials Browser

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT05118724 2025-06-15

ANTONIO

Phase 2 Active not recruiting

80 enrolled

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT06646445 2025-06-13

PREMICES

Phase 2 Not yet recruiting

60 enrolled

Gastrointestinal

Turcot syndrome, Colonic Neoplasms, Microsatellite Instability

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

39 enrolled

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05426005 2025-03-19

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Phase 1/2 Recruiting

28 enrolled

Gastrointestinal

Turcot syndrome, Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Phase EARLY_PHASE1 Terminated

2 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

NCT05200559 2024-12-05

T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors

Phase 1/2 Recruiting

70 enrolled

Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Phase NA Not yet recruiting

10 enrolled

Gynecologic

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Phase 1/2 Recruiting

20 enrolled

Gastrointestinal

Turcot syndrome, Rectal Neoplasms

NCT02992964 2024-04-02

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Phase 1/2 Terminated

11 enrolled

Turcot syndrome

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

747 enrolled

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05371197 2022-05-12

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Phase 2 Unknown

26 enrolled

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT04001101 2021-11-30

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Phase 2 Withdrawn

Gastrointestinal

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT03150706 2020-04-03

Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Phase 2 Unknown

33 enrolled

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms